Contributions of estrogen to ER-negative breast tumor growth

Journal of Steroid Biochemistry and Molecular Biology

Volumn 102, Issue 1-5 SPEC. ISS., 2006, Pages 71-78

  Gupta, Piyush B ^a   Kuperwasser, Charlotte ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow; Breast cancer; ER; Estrogen; Stroma

Indexed keywords

BREAST NEOPLASMS; DISEASE PROGRESSION; ESTROGENS; HUMANS; RECEPTORS, ESTROGEN;

EID: 33750970564     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.09.025     Document Type: Article

References (62)

1. Pike M.C., Spicer D.V., Dahmoush L., and Press M.F. Estogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15 1 (1993) 17-35
2. Hulka B.S. Epidemiology of susceptibility to breast cancer. Genet. Cancer Susceptibility (1996) 159-174
3. Kelsey J.L., and Gammon M.D. The epidemiology of breast cancer. Cancer J. Clin. 41 (1991) 146-165
4. Pathak D.R., Osuch J.R., and He J. Breast carcinoma etiology: current knowledge and new insights into the effects of reproductive and hormonal risk factors in black and white populations. Cancer 88 Suppl. 5 (2000) 1230-1238
5. Pike M.C., and Spicer D.V. Hormonal contraception and chemoprevention of female cancers. Endocr. Relat. Cancer 7 2 (2000) 73-83
6. Armitage P., and Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 91 12 (2004) 1983-1989
7. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339 (8785) (1992) 71-85.
8. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 11 (2004) 1081-1092
9. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., Norton L., Nickelsen T., Bjarnason N.H., Morrow M., Lippman M.E., Black D., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281 (1999) 2189-2197
10. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., and Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 9354 (2003) 296-300
11. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349 19 (2003) 1793-1802
12. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17. J. Natl. Cancer Inst. 97 17 (2005) 1262-1271
13. Boyd S. On oophorectomy in cancer of the breast. Br. Med. J. 2 (1900) 1161-1167
14. Nissen-Meyer R. Prophylactic endocrine treatment in carcinoma of the breast. Clin. Radiol. 15 (1964) 152-160
15. Nissen-Meyer R. Endocrine treatment of breast cancer. Acta Unio Int. Contra Cancrum 20 (1964) 531-534
16. Nissen-Meyer R. Prophylactic ovariectomy and ovarian irradiation in breast cancer. Acta Unio Int. Contra Cancrum 20 (1964) 527-530
17. Lewison E.F. Castration in the treatment of advanced breast cancer. Cancer 18 12 (1965) 1558-1562
18. Fisher B. Status of adjuvant therapy: results of The National Surgical Adjuvant Breast Project studies on oophorectomy, postoperative radiation therapy, and chemotherapy. Other comments concerning clinical trials. Cancer 28 6 (1971) 1654-1658
19. Sander S. The capacity of breast tissue to accumulate oestradiol-17-beta in vitro. Acta Pathol. Microbiol. Scand. 73 1 (1968) 29-36
20. Sander S. The in vitro uptake of oestradiol in biopsies from 25 breast cancer patients. Acta Pathol. Microbiol. Scand. 74 2 (1968) 301-302
21. McGuire W.L. Estrogen receptors in human breast cancer. J. Clin. Invest. 52 1 (1973) 73-77
22. Johansson H., Terenius L., and Thoren L. The binding of estradiol-17beta to human breast cancers and other tissues in vitro. Cancer Res. 30 3 (1970) 692-698
23. Feherty P., Farrer-Brown G., and Kellie A.E. Oestradiol receptors in carcinoma and benign disease of the breast: an in vitro assay. Br. J. Cancer 25 4 (1971) 697-710
24. Steggles A.W., and King R.J. The use of protamine to study [6,7-3H] oestradiol-17-beta binding in rat uterus. Biochem. J. 118 5 (1970) 695-701
25. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339 (8784) (1992) 1-15.
26. Lubahn D.B., Moyer J.S., Golding T.S., Couse J.F., Korach K.S., and Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl. Acad. Sci. U.S.A. 90 23 (1993) 11162-11166
27. Zhu Y., Ghosh P., Charnay P., Burns D.K., and Parada L.F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296 5569 (2002) 920-922
28. Shim G.J., Wang L., Andersson S., Nagy N., Kis L.L., Zhang Q., Makela S., Warner M., and Gustafsson J.A. Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Proc. Natl. Acad. Sci. U.S.A. 100 11 (2003) 6694-6699
29. Karas R.H., Schulten H., Pare G., Aronovitz M.J., Ohlsson C., Gustafsson J.A., and Mendelsohn M.E. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ. Res. 89 6 (2001) 534-539
30. Johns A., Freay A.D., Fraser W., Korach K.S., and Rubanyi G.M. Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology 137 10 (1996) 4511-4513
31. Maggi A., Ciana P., Belcredito S., and Vegeto E. Estrogens in the nervous system: mechanisms and nonreproductive functions. Annu. Rev. Physiol. 66 (2004) 291-313
32. Bakir S., Mori T., Durand J., Chen Y.F., Thompson J.A., and Oparil S. Estrogen-induced vasoprotection is estrogen receptor dependent: evidence from the balloon-injured rat carotid artery model. Circulation 101 20 (2000) 2342-2344
33. Karas R.H., Hodgin J.B., Kwoun M., Krege J.H., Aronovitz M., Mackey W., Gustafsson J.A., Korach K.S., Smithies O., and Mendelsohn M.E. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc. Natl. Acad. Sci. U.S.A. 96 26 (1999) 15133-15136
34. Katzenellenbogen B.S., and Katzenellenbogen J.A. Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2 5 (2000) 335-344
35. Mendelsohn M.E. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean?. Circ. Res. 87 11 (2000) 956-960
36. Katzenellenbogen B.S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod. 54 2 (1996) 287-293
37. Kousteni S., Chen J.R., Bellido T., Han L., Ali A.A., O'Brien C.A., Plotkin L., Fu Q., Mancino A.T., Wen Y., Vertino A.M., Powers C.C., et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298 5594 (2002) 843-846
38. Manolagas S.C., Kousteni S., Chen J.R., Schuller M., Plotkin L., and Bellido T. Kinase-mediated transcription, activators of nongenotropic estrogen-like signaling (ANGELS), and osteoporosis: a different perspective on the HRT dilemma. Kidney Int. Suppl. 91 (2004) S41-S49
39. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93 12 (1996) 5925-5930
40. Rebbeck T.R. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 18 suppl. 21 (2000) S100-S103
41. Chappuis P.O., Nethercot V., and Foulkes W.D. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin. Surg. Oncol. 18 4 (2000) 287-295
42. Putti T.C., El-Rehim D.M., Rakha E.A., Paish C.E., Lee A.H., Pinder S.E., and Ellis I.O. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod. Pathol. 18 1 (2005) 26-35
43. Locker G.Y. Hormonal therapy of breast cancer. Cancer Treat. Rev. 24 3 (1998) 221-240
44. Buteau-Lozano H., Ancelin M., Lardeux B., Milanini J., and Perrot-Applanat M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res. 62 17 (2002) 4977-4984
45. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., and Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 5331 (1997) 1508-1510
46. Jensen E.V., Cheng G., Palmieri C., Saji S., Makela S., Van Noorden S., Wahlstrom T., Warner M., Coombes R.C., and Gustafsson J.A. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc. Natl. Acad. Sci. U.S.A. 98 26 (2001) 15197-15202
47. Almeida M., Han L., O'Brien C.A., Kousteni S., and Manolagas S.C. Classical genotropic versus kinase-initiated regulation of gene transcription by the estrogen receptor alpha. Endocrinology (2005)
48. Krishnan V., Heath H., and Bryant H.U. Mechanism of action of estrogens and selective estrogen receptor modulators. Vit. Horm. 60 (2000) 123-147
49. Murphy H.S., Sun Q., Murphy B.A., Mo R., Huo J., Chen J., Chensue S.W., Adams M., Richardson B.C., and Yung R. Tissue-specific effect of estradiol on endothelial cell-dependent lymphocyte recruitment. Microvasc. Res. 68 3 (2004) 273-285
50. Dotzlaw H., Leygue E., Watson P.H., and Murphy L.C. Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res. 59 3 (1999) 529-532
51. Villadsen R. In search of a stem cell hierarchy in the human breast and its relevance to breast cancer evolution. APMIS 113 11-12 (2005) 903-921
52. Clarke R.B., Spence K., Anderson E., Howell A., Okano H., and Potten C.S. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev. Biol. 277 2 (2005) 443-456
53. Clarke R.B. Ovarian steroids and the human breast: regulation of stem cells and cell proliferation. Maturitas 54 4 (2006) 327-334
54. Palmieri C., Saji S., Sakaguchi H., Cheng G., Sunters A., O'Hare M.J., Warner M., Gustafsson J.A., Coombes R.C., and Lam E.W. The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J. Mol. Endocrinol. 33 1 (2004) 35-50
55. Sapino A., Bosco M., Cassoni P., Castellano I., Arisio R., Cserni G., Tos A.P., Fortunati N., Catalano M.G., and Bussolati G. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod. Pathol. 19 4 (2006) 599-606
56. Ashcroft G.S., Dodsworth J., van B.E., Tarnuzzer R.W., Horan M.A., Schultz G.S., and Ferguson M.W. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat. Med. 3 11 (1997) 1209-1215
57. Kahlert S., Nuedling S., van E.M., Vetter H., Meyer R., and Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 275 24 (2000) 18447-18453
58. Albuquerque M.L., Akiyama S.K., and Schnaper H.W. Basic fibroblast growth factor release by human coronary artery endothelial cells is enhanced by matrix proteins, 17beta-estradiol, and a PKC signaling pathway. Exp. Cell Res. 245 1 (1998) 163-169
59. de Visser K.E., Korets L.V., and Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7 5 (2005) 411-423
60. Condeelis J., and Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 2 (2006) 263-266
61. Banka C.L., Lund C.V., Nguyen M.T., Pakchoian A.J., Mueller B.M., and Eliceiri B.P. Estrogen induces lung metastasis through a host compartment-specific response. Cancer Res. 66 7 (2006) 3667-3672
62. P.B. Gupta, D. Proia, J. Weremowicz, S.P. Naber, R.A. Weinberg, C. Kuperwasser. Systemic effects of estrogen promotes the growth of estrogen receptor-negative cancers, submitted for publication.